arthyperАртериальная гипертензия"Arterial’naya Gipertenziya" ("Arterial Hypertension")1607-419X2411-8524Antihypertensive League10.18705/1607-419X-2005-11-1-24-28arthyper-1002Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL ARTICLESОпыт применения нолипрела и его сочетания с заместительной гормональной терапией у женщин с гипертонической болезнью в постменопаузеExperience in using noliprel and its combination with hormonal replacement therapy in women with postmenopausal hypertensive diseaseБарановаЕ. И.BaranovaYe. I.noemail@neicon.ruБольшаковаО. О.BolshakovaO. O.noemail@neicon.ruМасловаΗ. П.MaslovaN. P.noemail@neicon.ruКацапА. А.KatsapA. A.noemail@neicon.ruМанихасО. С.ManikhasO. S.noemail@neicon.ruВоронинаУ. В.VoroninaU. V.noemail@neicon.ruТуровцеваТ. Ю.TurovtsevaT. Yu.noemail@neicon.ruРепинаМ. А.RepinaM. A.noemail@neicon.ruКорниловаЯ. А.KornilovaYa. A.noemail@neicon.ruСанкт-Петербургский государственный медицинский университет им. акад. И.П.ПавловаRussian FederationСанкт-Петербургская медицинская академия последипломного образования М3 и СР РФRussian Federation2005280220051112428Copyright © Баранова Е.И., Большакова О.О., Маслова Η.П., Кацап А.А., Манихас О.С., Воронина У.В., Туровцева Т.Ю., Репина М.А., Корнилова Я.А., 20052005Баранова Е.И., Большакова О.О., Маслова Η.П., Кацап А.А., Манихас О.С., Воронина У.В., Туровцева Т.Ю., Репина М.А., Корнилова Я.А.Baranova Y.I., Bolshakova O.O., Maslova N.P., Katsap A.A., Manikhas O.S., Voronina U.V., Turovtseva T.Y., Repina M.A., Kornilova Y.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://htn.almazovcentre.ru/jour/article/view/1002

Цель работы изучение эффективности и переносимости фиксированной низкодозовой комбинации периндоприла и индапамида и ее сочетания с заместительной гормональной терапией у женщин с гипертонической болезнью в постменопаузе Материал и методы обследованы 63 женщины с эссенциальной гипертензией I—II степени и климактерическим синдромом Больные были рандомизированы для получения антигипертензивной терапии нолипрелом (группа 1) или его сочетания с заместительной гормональной терапией (группа 2) Проводили измерение артериального дав ления (АД) по методу Н С Короткова, суточное мониторирование АД (СМАД), эхокардиографию, исследовали показатели липидного спектра, уровень глюкозы, креатинина, калия и мочевой кислоты в плазме крови, определяли качество жизни с помощью модифицированного менопаузального индекса Результаты отмечена хорошая субъективная переносимость терапии и снижение менопаузального индекса в обеих группах Эффективность антигипертензивной терапии в группе 1 составила 92,7%, в группе 2 - 95,2% По результатам СМАД степень снижения АД и нагрузки давлением в группе 2 была достоверно больше, чем в группе 1 Не отмечено негативного влияния терапии на метаболические показатели ни в одной группе Заключение Таким образом, нолипрел является эффективным препаратом для лечения женщин с гипертонической болезнью в постменопаузе Заместительная гормональная терапия способствует увеличению антигипертензивного эффекта нолипрела и не влияет на его метаболическую нейтральность

Objective to evaluate the efficacy and tolerability of fixed low-dose combination of permdopnl and indapamide and its co-administration with hormonal replacement therapy in women with postmenopausal hypertensive disease Materials and methods 63 women with grade 1-2 essential hypertension and postmenopausal syndrome were examined The patients were randomized to receive antihypertensive therapy with noliprel (Group 1) or its combination with hormonal replacement therapy (Group 2) The authors made blood pressure (BP) measurements by the Korotkoff method, 24-hour BP monitoring, echocardiography, studied the lipid spectrum, the plasma levels of glucose, creatinine, potassium, and uric acid, and determined life quality with the modified menopausal index Results A good subjective tolerability of therapy and a decrease in the menopausal index were noted in both groups The efficiency of antihypertensive therapy was 92 7% in Group 1 and 95 2% in Group 2 24-hour BP monitoring showed that the reduction in BP and pressure load was significantly higher in Group 2 than in Group 1 The therapy has no negative impact on metabolic parameters in both groups Conclusion Thus, noliprel is an effective drug in treating postmenopausal women with hypertensive disease Hormonal replacement therapy contributes to the higher antihypertensive effect of noliprel and exerts no effect on its metabolic neutrality

постменопаузафиксированная низкодозовая комбинация периндоприла и индапамидагормональная заместительная терапияpostmenopausefixed low-dose combination of penndopnl and indapamidehormonal replacement therapyReferencesMercuro G., Zoncu S., Saiu F. et al. Menopause induce by oophorectomy reveales a role of ovarian estrogen on the maintenance of pressure home ostasis Matuntas 2004, 47 131-8Mercuro G., Zoncu S., Saiu F. et al. Menopause induce by oophorectomy reveales a role of ovarian estrogen on the maintenance of pressure home ostasis Matuntas 2004, 47 131-8Pines A. Hormone therapy and the cardiovascular system Matuntas 2002, 43 (suppl) S3-S10Pines A. Hormone therapy and the cardiovascular system Matuntas 2002, 43 (suppl) S3-S10Writing Group for the 3rd European Conference on Sex Steroids and Cardiovascular Diseases The European Consensus Development Conference 2002 Sex steroids and cardiovascular diseases On the route to combine evidence from ОС and HRT/ERT Matuntas 2003, 44 69-82Writing Group for the 3rd European Conference on Sex Steroids and Cardiovascular Diseases The European Consensus Development Conference 2002 Sex steroids and cardiovascular diseases On the route to combine evidence from ОС and HRT/ERT Matuntas 2003, 44 69-82Баранова Е.И., Маслова Н.П. Гипертоническая болезнь у женщин СПб Изд-во СПбГМУ, 2000Баранова Е.И., Маслова Н.П. Гипертоническая болезнь у женщин СПб Изд-во СПбГМУ, 2000Affinto P., Palomba S., Bonifacio M. et al. Effects of hormonal replacement therapy m postmenopausal hypertensive patients Matuntas 2001, 40 75-83Affinto P., Palomba S., Bonifacio M. et al. Effects of hormonal replacement therapy m postmenopausal hypertensive patients Matuntas 2001, 40 75-83Baker L., Meldrum K., Wang M. et al. The role of estrogen m cardiovascular disease J Surg Res 2003, 115 325-44Baker L., Meldrum K., Wang M. et al. The role of estrogen m cardiovascular disease J Surg Res 2003, 115 325-44Кобалава Ж.Д., Котовская Ю.В. Мониторирование артериального давления методические аспекты и клиническое значение М, 1999Кобалава Ж.Д., Котовская Ю.В. Мониторирование артериального давления методические аспекты и клиническое значение М, 1999Kenemans Р., van Unnik G., Myatovic V., van der Mooren M. Perspectives in hormone replacement therapy Matuntas 2001, 38 (suppl) S41-S48Kenemans Р., van Unnik G., Myatovic V., van der Mooren M. Perspectives in hormone replacement therapy Matuntas 2001, 38 (suppl) S41-S48Staessen J., Bulpitt C., Fagard R. et al. The influence if menopause on blood pressure Hypertension in postmenopausal women Spnnger-Verlag, Berlin, 1994, p 15-26Staessen J., Bulpitt C., Fagard R. et al. The influence if menopause on blood pressure Hypertension in postmenopausal women Spnnger-Verlag, Berlin, 1994, p 15-26Zabalgoitia M., Rahman S., Haley W. et al. Companson of left ventncular mass andgeometnc remodeling in treated and untreated men and women more than 50 years of age with systemic hypertension Am J Cardiol 1997, 80 648-51Zabalgoitia M., Rahman S., Haley W. et al. Companson of left ventncular mass andgeometnc remodeling in treated and untreated men and women more than 50 years of age with systemic hypertension Am J Cardiol 1997, 80 648-51Genazzam A. Controversial issues in climactenc medicine Cardiovascular disease and hormone replacement therapy International Menopause Society Expert Workshop, 13-16 October 2000, Royal Society of Medicine, London, UK Matuntas 2000, 38 263-71Genazzam A. Controversial issues in climactenc medicine Cardiovascular disease and hormone replacement therapy International Menopause Society Expert Workshop, 13-16 October 2000, Royal Society of Medicine, London, UK Matuntas 2000, 38 263-71Mallion J., Chastang C., Unger P. Efficacy and safety of a fixed low-dose penndopril/indapamide combination in essential hypertension a randomized controlled study Clin Exp Hypertens 2000, 22 23-32Mallion J., Chastang C., Unger P. Efficacy and safety of a fixed low-dose penndopril/indapamide combination in essential hypertension a randomized controlled study Clin Exp Hypertens 2000, 22 23-32Carretero O., Opanl S. Essential hypertension Parti definition and etiol ogy Circulation 2000, 101 329-35Carretero O., Opanl S. Essential hypertension Parti definition and etiol ogy Circulation 2000, 101 329-35Chalmers J., Castaigne A., Morgan T., Chastang С. Long-term efficacy of a new fixed very low dose angiotensin coverting enzyme inhibitor/diuretic combination as first line therapy in the elderly hypertensive patients Am J Hypertens 2000, 18 327-37Chalmers J., Castaigne A., Morgan T., Chastang С. Long-term efficacy of a new fixed very low dose angiotensin coverting enzyme inhibitor/diuretic combination as first line therapy in the elderly hypertensive patients Am J Hypertens 2000, 18 327-37Галеева 3.M., Галявич А.С. Влияние фиксированной низкодозовой комбинации гипотензивных препаратов на клинико-биохимические характеристики больных артериальной гипертензией Артериальн гипертенз 2003, 9 (6) 221-4Галеева 3.M., Галявич А.С. Влияние фиксированной низкодозовой комбинации гипотензивных препаратов на клинико-биохимические характеристики больных артериальной гипертензией Артериальн гипертенз 2003, 9 (6) 221-4Chanudet X., Phong Chau N., De Champvallms M. Very-low -dose penndopril 2 mg/indapamide 0,625 mg combination gives higher response and normalization routes than lozartan 50 mg in the treatment of essential hypertension Am J Hypert 2000, 4 140Chanudet X., Phong Chau N., De Champvallms M. Very-low -dose penndopril 2 mg/indapamide 0,625 mg combination gives higher response and normalization routes than lozartan 50 mg in the treatment of essential hypertension Am J Hypert 2000, 4 140Psaty B., Heckbert S., Atkins D. et al. The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women Arch Intern Med 1994 154 1333-9Psaty B., Heckbert S., Atkins D. et al. The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women Arch Intern Med 1994 154 1333-9Stampfer M., Colditz G., Willet W. et al. Postmenopausal estrogen therapy and cardiovascular disease Ten-year follow-up from the nurses' health study N Eng ] Med 1991, 253 756-62Stampfer M., Colditz G., Willet W. et al. Postmenopausal estrogen therapy and cardiovascular disease Ten-year follow-up from the nurses' health study N Eng ] Med 1991, 253 756-62Hemminki E., McPherson К Impact of postmenopausal hormone thera py on cardiovascular events and cancer pooled data from clinical tnals BMJ 1997,315 149-53Hemminki E., McPherson К Impact of postmenopausal hormone thera py on cardiovascular events and cancer pooled data from clinical tnals BMJ 1997,315 149-53Hulley S., Grady D., Bush T et al. Randomized trial of estrogen plus prog estin for secondary prevention of coronary heart disease in post menopausal women Heart and Estrogen/progestin Replacement Study (HERS) Research Group JAMA 1998, 280 605Hulley S., Grady D., Bush T et al. Randomized trial of estrogen plus prog estin for secondary prevention of coronary heart disease in post menopausal women Heart and Estrogen/progestin Replacement Study (HERS) Research Group JAMA 1998, 280 605Wnting Group for the Women's Health Initiative investigators Risks and benefits of estrogen plus progestin in healthy postmenopausal women pnncipal results from the women's health initiative randomized controlled tnal JAMA 2002, 288 321-33Wnting Group for the Women's Health Initiative investigators Risks and benefits of estrogen plus progestin in healthy postmenopausal women pnncipal results from the women's health initiative randomized controlled tnal JAMA 2002, 288 321-33Maas A., van der Graaf Y., tan der Schouw Y. Grobbee D HRT and heart disease problema and prospects Matuntas 2004, 47 255-8Maas A., van der Graaf Y., tan der Schouw Y. Grobbee D HRT and heart disease problema and prospects Matuntas 2004, 47 255-8Manson J., Martin К. Postmenopausal hormone replacement therapy N Engl J Med 2001, 345 34-40Manson J., Martin К. Postmenopausal hormone replacement therapy N Engl J Med 2001, 345 34-40Ynkorkala О. HRT as secondary prevention of cardiovascular disease Matuntas 2004,47 315-8Ynkorkala О. HRT as secondary prevention of cardiovascular disease Matuntas 2004,47 315-8Haywards C., Samaras K., Campbell L., Kelly R. Effect of combination hor топе replacement therapy on ambulatory blood pressure and artenal stiffness m diabetic postmenopausal women Am J Hypert 2002, 14 (7) 699-703Haywards C., Samaras K., Campbell L., Kelly R. Effect of combination hor топе replacement therapy on ambulatory blood pressure and artenal stiffness m diabetic postmenopausal women Am J Hypert 2002, 14 (7) 699-703Lip G., Beevers M., Churchill D., Beevers D. Hormone replacement therapy and blood pressure m hypertensive women J Hum Hypertens 1994, 8 (7) 491-4Lip G., Beevers M., Churchill D., Beevers D. Hormone replacement therapy and blood pressure m hypertensive women J Hum Hypertens 1994, 8 (7) 491-4Szekacs B., Vajo Z., Acs N. et al. Hormone replacement therapy reduces mean 24 hour blood pressure and its vanability m postmenopausal women with treated hypertension Menopause 2000, 7 31-5Szekacs B., Vajo Z., Acs N. et al. Hormone replacement therapy reduces mean 24 hour blood pressure and its vanability m postmenopausal women with treated hypertension Menopause 2000, 7 31-5Van Ittersum F., van Baal W., Kenemans P. et al. Ambulatory - not office -blood pressure decline dunng hormone replacement therapy m healthy postmenopausal women Am J Hypertens 1998, 11 (10) 1147-52Van Ittersum F., van Baal W., Kenemans P. et al. Ambulatory - not office -blood pressure decline dunng hormone replacement therapy m healthy postmenopausal women Am J Hypertens 1998, 11 (10) 1147-52Vestergaard P., Hermann A., Stilgren L. et al. Effects of 5 years of hormonal replacement therapy on menopausal symptoms and blood pressure - a randomized controlled study Matuntas 2003, 46 123-32Vestergaard P., Hermann A., Stilgren L. et al. Effects of 5 years of hormonal replacement therapy on menopausal symptoms and blood pressure - a randomized controlled study Matuntas 2003, 46 123-32Butkevich A., Abraham C., Phillips R. Hormone replacement therapy and 24-hour blood pressure profile of postmenopausal women Am J Hypertens 2000, 13 (9) 1039-41Butkevich A., Abraham C., Phillips R. Hormone replacement therapy and 24-hour blood pressure profile of postmenopausal women Am J Hypertens 2000, 13 (9) 1039-41Genazzam A., Gambacciam M. Hormone replacement therapy the per spectives for the 21 st century Matuntas 1999, 32 11-7Genazzam A., Gambacciam M. Hormone replacement therapy the per spectives for the 21 st century Matuntas 1999, 32 11-7Morales D., McGowan K., Grant D. et al. Circulation 1995, 91 755-63Morales D., McGowan K., Grant D. et al. Circulation 1995, 91 755-63Spyndopoulos I., Sullivan A., Kearney M. et al. Estrogen receptor-mediated inhibition of human endothelial cell apoptosis estradiol as a survival factor Circulation 1997,95 1505-14Spyndopoulos I., Sullivan A., Kearney M. et al. Estrogen receptor-mediated inhibition of human endothelial cell apoptosis estradiol as a survival factor Circulation 1997,95 1505-14Pagamm-Hill A Hormone replacement therapy and stroke nsk,protection of no effect? Matuntas 2001, 38 243-61Pagamm-Hill A Hormone replacement therapy and stroke nsk,protection of no effect? Matuntas 2001, 38 243-61Landau R., Poulos J. The metabolic influence of progestins Ad Vol. Metab Disord 1971,5 U9-47Landau R., Poulos J. The metabolic influence of progestins Ad Vol. Metab Disord 1971,5 U9-47Sealey J., Itskovitz-Eldor J., Rubattu S. et al. Estradiol and progesterone related increases in renmn aldosterone system dunng ovanan stimulation and early pregnancy J Clm Endocr Metab 1994, 79 258-64Sealey J., Itskovitz-Eldor J., Rubattu S. et al. Estradiol and progesterone related increases in renmn aldosterone system dunng ovanan stimulation and early pregnancy J Clm Endocr Metab 1994, 79 258-64Караченцов A.H., Сергеев В.П. Вазоактивные эффекты половых гормонов Пробл эндокр 1997,41 (2) 45-53Караченцов A.H., Сергеев В.П. Вазоактивные эффекты половых гормонов Пробл эндокр 1997,41 (2) 45-53Barbagallo М., Shan J., Pang P., Resnik L. Vascular effects of progesterone role of intracellular calcium metabolism Am J Hypertens 1995, 8 66ABarbagallo М., Shan J., Pang P., Resnik L. Vascular effects of progesterone role of intracellular calcium metabolism Am J Hypertens 1995, 8 66AKarjalainen A., Rushkoabo H., Vuolteenaho О. et al. Effect of estrogen replacement therapy on natnuretic peptides and blood pressure Matuntas 2004,47 201-8Karjalainen A., Rushkoabo H., Vuolteenaho О. et al. Effect of estrogen replacement therapy on natnuretic peptides and blood pressure Matuntas 2004,47 201-8

The authors declare that there are no conflicts of interest present.